Jon Chesebrough

Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy.

R. Tammali, N. Monks, Ashley A. Merlino, 2022, Cytotherapy.

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

M. Tabrizi, D. Blakey, S. Coats, 2011, Cancer research.

Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling

E. Hurt, R. Hollingsworth, Youzhen Wang, 2013, Molecular Cancer Therapeutics.

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2–positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib

D. Jackson, S. Coats, B. Jallal, 2009, Molecular Cancer Therapeutics.

Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.

R. Hollingsworth, N. Dimasi, R. Fleming, 2017, Cancer Research.

A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways

R. Hollingsworth, J. Friedman, R. Tammali, 2015, Molecular Cancer Therapeutics.

Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

R. Hollingsworth, Wei Zhao, C. Leow, 2015, Neoplasia.

Spatial Analysis of Key Signaling Proteins by High-content Solid-phase Cytometry in Hep3B Cells Treated with an Inhibitor of Cdc25 Dual-specificity Phosphatases*

J. Lazo, B. Carr, A. Vogt, 2001, The Journal of Biological Chemistry.

Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.

M. Albertella, Z. Cooper, R. Christie, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

M. Tabrizi, D. Blakey, S. Coats, 2011, Cancer research.

A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways

R. Hollingsworth, R. Tammali, C. Leow, 2015, Molecular Cancer Therapeutics.